Open Access Open Access  Restricted Access Subscription or Fee Access

Swarna Bhasma as a Nanomedicine in Ayurveda: A Comprehensive Review on its Efficacy in Remediation of Rheumatoid Arthritis, an Autoimmune Disorder

Padmanav Koushik, Jyotsna Dayma

Abstract


Swarna Bhasma, a key component in Ayurvedic medicine, has gained attention as a promising nanomedicine for the treatment of autoimmune disorders, particularly Rheumatoid Arthritis (RA). This ancient therapeutic formulation involves the purification and calcination of gold, rendering it into a nano-
sized particle known as Swarna Bhasma. Ayurveda, with its holistic approach, recognizes the significance of this nanomedicine in addressing the root causes of autoimmunity and RA, providing a potential avenue for permanent relief. The unique properties of Swarna Bhasma lie in its ability to modulate the immune
response and restore the balance disrupted in autoimmune conditions. Research suggests that the nano-sized gold particles possess anti-inflammatory and immunomodulatory effects, influencing various signaling pathways associated with autoimmunity. Moreover, Swarna Bhasma is believed to enhance the
bioavailability of gold, ensuring efficient delivery to target tissues and cells. In the context of RA, the present review presents the Swarna Bhasma as a permanent therapeutic solution. Its multifaceted approach involves not only alleviating symptoms but also addressing the underlying immune dysregulation. By promoting self-tolerance and regulating the immune system, Swarna Bhasma aims to disrupt the progression of RA, providing long-term relief to patients. As the field of nanomedicine continues to evolve, Swarna Bhasma, being a nature’s boon emerges as a beacon of hope in the management of autoimmune disorders, offering a holistic and sustainable approach rooted in Ayurvedic
principles. Further exploration and clinical studies are warranted to validate its efficacy, paving the way for the integration of this traditional nanomedicine into contemporary healthcare practices.


Keywords


Rheumatoid arthritis, Amavata, Nanomedicine, Swarna Bhasma, Autoimmunity, Osteoarthritis.

Full Text:

PDF

References


Ferrari M. Cancer nanotechnology: Opportunities and challenges. Nat Rev Cancer. 2005; 5(3): 161–171.

Wagner V, Dullaart A, Bock AK. The emerging nanomedicine landscape. Nat Biotechnol. 2006;24(10): 1211–1217.

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1–2): 271–284.

Hua S, Wu SY, Thevenot J. Advances in nanotheranostics II: strategies and applications.Nanomedicine. 2018; 13(7): 823–826.

Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for

cancer. Nat Rev Drug Discov. 2008; 7(9): 771–782.

Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat

Rev Drug Discov. 2010; 9(8): 615–627.

Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009; 3(1): 16–20.

Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017; 17(1): 20–37.

Kim J, Piao Y, Hyeon T. Multifunctional nanostructured materials for multimodal imaging, andsimultaneous imaging and therapy. Chem Soc Rev. 2010; 39(2): 367–374.

Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010; 376(9746): 1094–1108.

McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011; 365(23):2205–2219.

Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2013; 381(9871): 1741–1754.

Smolen JS, Aletaha D, McInnes IB, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2016; 2: 16016.

Sokolove J, Kavanaugh A. Epidemiology of rheumatoid arthritis: Risk factors and environmental influences. Nat Rev Rheumatol. 2014; 10(8): 581–591.

Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. AnnRheum Dis. 2010; 69(9): 1580–1588.

Smolen JS, Landewé RB, Bijlsma JW, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016update. Ann Rheum Dis. 2017; 76(6): 960–977.

Singh JA, Furst DE. Bharat rheumatoid arthritis agents for disease control (RADC) Study. Arthritis

Res Ther. 2014; 16(1): R25.

Smolen JS, Burmester GR, Combe B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet. 2020; 395(10226): 1204–1214.

Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2016; 376(7): 652–662.

Combe B, Landewe R, Daien CI, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2017; 76(6): 948–959.

Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study. Arthritis Rheum.2020; 46(9): 2287–2293.

Okada Y, Wu D, Trynka G, et al. Genetics of rheumatoid arthritis contributes to biology and drugdiscovery. Nature. 2014; 506(7488): 376–381. https://doi.org/10.1038/nature12873.

Haroon E, Daguanno AW, Woolwine BJ, Goldsmith DR, Baer WM, Wommack EC, Felger JC,Miller AH. Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder. Psychoneuroendocrinology. 2018 Sep; 95: 43–49. doi:10.1016/j.psyneuen.2018.05.026. Epub 2018 May 19. PMID: 29800779; PMCID: PMC6427066.

Nivedita Rawat, Sharddha Sharma. Role of Ayurvedic Medicinal Plants in Auto-immune disordersand their management. J Ayu Int Med Sci. 2023; 8(3): 108–115. Available Fromhttps://jaims.in/jaims/article/view/2343

Kumar G, Srivastava A, Sharma SK, Rao TD, Gupta YK. Efficacy & safety evaluation of Ayurvedictreatment (Ashwagandha powder & Sidh Makardhwaj) in rheumatoid arthritis patients: a pilotprospective study. Indian J Med Res. 2015 Jan; 141(1): 100–6. doi: 10.4103/0971-5916.154510.PMID: 25857501; PMCID: PMC4405924.

Chandran B, Patwardhan B. Network pharmacology of ayurveda formulation ashwagandharishta.Indian J Pharm Sci. 2016; 78(1): 161–170.

Bizzaro G, Antico A, Fortunato A, Bizzaro N. Vitamin D and autoimmune diseases: Is vitamin Dreceptor (VDR) polymorphism the culprit. ISR Med Assoc J. 2017 Jul;19(7):438–443.

Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera(ashwagandha): A review. Altern Med Rev. 2000; 5(4): 334–346.

Murthy KN, Reddy VK, Veerappan R, Varalakshmi C. Evaluation of the anti-arthritic effects of siddha makardhwaja on adjuvant-induced arthritis in wistar rats. Pharmacognosy Res. 2019; 11(4):365–372.

Sharma N, Shukla S, Kapoor M, Dubey S, Bhatia A, Mishra P, Sharma RK, et al. Siddha makardhwaja, an ayurvedic medicine, prevents autoimmune arthritis by modulating inflammatory

mediators and oxidative stress. J Ethnopharmacol. 2021; 269: 113709.

Sharma SD, Trivedi V, Dadheech G, Bhatnagar M. Mercury-based Indian traditional formulation: An overview of safety aspects. J Toxicol. 2018; 2018: 1–11.

Paul W, Sharma CP. Blood compatibility studies of Swarna bhasma(gold bhasma), an Ayurvedic drug. Int J Ayurveda Res. 2011 Jan; 2(1): 14–22. doi: 10.4103/0974-7788.83183. PMID: 21897638;

PMCID: PMC3157103.

Patwardhan B, Vaidya AD. Natural products drug discovery: Accelerating the clinical candidate development using reverse pharmacology approaches. Indian J Exp Biol. 2010; 48(3): 220–7.

Sonavanea G, Tomoda K, Sano A, Ohshima H, Terada H, Makino K. In vitro permeation of gold nanoparticles through rat skin and rat intestine: Effect of particle size. Colloids Surf B:Biointerfaces. 2008; 65(1): 1–10.

Batheja P, Thakur R, Michniak B. Basic biopharmaceutics of buccal and sublingual absorption. In:Touitou E, Barry BW, editors. In Enhancement in Drug Delivery. New York:CRC Press; 2007.

Shah ZA, Vohora SB. Antioxidant/Restorative Effects of Calcined Gold Preparations Used in Indian Systems of Medicine against Global and Focal Models of Ischaemia. Pharmacol Toxicol.2002; 90(5): 254–9.

Mitra A, Chakraborty S, Auddy B, Tripathi T, Sen S, Saha AV, et al. Evaluation of chemical constituents and free-radical scavenging activity of Swarnabhasma (gold ash), an Ayurvedic drug.J Ethnopharmacol. 2002; 80(2–3): 147–53.

Ghosh P, Han G, De M, Kim CK, Rotello VM. Gold nanoparticles in delivery applications. Adv Drug Deliv Rev. 2008; 60(11): 1307–15.

Liu Y, Shipton MK, Ryan J, Kaufman ED, Franzen S, Feldheim DL. Synthesis, Stability, and Cellular Internalization of Gold Nanoparticles Containing Mixed Peptide–Poly(ethylene glycol) Monolayers. Anal Chem. 2007; 79(6): 2221–9.

Brown CL, Bushell G, Whitehouse MW, Agrawal DS, Tupe SG, Paknikar KM, et al. Nanogold-pharmaceutics. Gold Bull. 2007; 40(3): 245–50.

Florence AT. Nanoparticle uptake by the oral route: Fulfilling its potential? Drug Discov Today Technol. 2005; 2(1): 75–81.

De Wall SL, Painter C, Stone JD, Bandaranaayake R, Wiley DC, Mitchison TJ, et al. Noble metals strip peptides from class II MHC proteins. Nat Chem Biol. 2006; 2(4): 197–201.

Sharma CP. Blood Compatible Materials: A Perspective. J Biomater Appl. 2001; 15(4): 359–81.

Lagad CE, Sawant RS, Yelambkar P. An approach towards standardization of Swarna Makshik Bhasma (An ayurvedic prepration) Int J Res Ayu Pharm. 2011; 2: 723–9.

Balasubramanian SK, Jittiwat J, Manikandan J, Ong CN, Yu LE, Ong WY. Biodistribution of gold nanoparticles and gene expression changes in the liver and spleen after intravenous administration in rats. Biomaterials. 2010; 31(8): 2034–42. [PubMed] [Google Scholar]

Paul W, Sharma CP. Blood compatibility studies of Swarna Bhasma (Gold Bhasma), an Ayurvedic drug. Int J Ayurveda Res. 2011; 2(1): 14–22.

Kean WF, Hart L, Buchanan WW. Auranofin. Br J Rheumatol. 1997; 36(5): 560–72.

Mohaptra S, Jha CB. Physicochemical characterization of ayurvedic Bhasma (Swarna makshikaBhasma): An approach to standardization. Int J Ayurveda Res. 2010; 1(2): 82–6.

Pal D, Sahu CK, Haldar A. Bhasma: The ancient Indian nanomedicine. J Adv Pharm Technol Res.2014 Jan; 5(1): 4–12. doi: 10.4103/2231-4040.126980. PMID:24696811; PMCID: PMC3960793.

De Miguel E, Arnalich F, Tato E, Vázquez JJ, Gijón-Baños J, Hernanz A. The effect of gold salts on substance P in the rheumatoid arthritis. Neurosci Lett. 1994; 174(2): 185–187.

Shraddha Sharma, Swatantra Kumar Chorasia, Arvind Kumar Yadav. The role of Swarna Bhasmain the treatment of Autoimmune disease. J Ayurveda Integr Med Sci. 2021; 6(4): 285–290. https://doi.org/10.21760/jaims.v6i4.1410

Snider Benjamin. (2013). Castor oil Handout. [Online].

Herting David C, Drury Emma Jane E. Vit. E content of vegetable Oils and Fats. J Nutr. 2013;81(4): 335–342.

Waghmare Sandip D, Waghmare Ranjana S. Ayurvedic Management of Severe Amavata(Rheumatoid Arthritis) with its Complications: A Case Study. Ayushdhara. 2019; 6(6): 2480–2483.




DOI: https://doi.org/10.37591/jonsnea.v13i3.1497

Refbacks

  • There are currently no refbacks.